[[{“value”:”
AbbVie is advancing its U.S. manufacturing platform with a $380 million investment to construct two new manufacturing facilities at its Illinois campus, expanding domestic production capacity for key neuroscience and obesity therapies. The biopharmaceutical company said the projects are aligned with its broader push to scale up U.S. manufacturing as part of a $100 billion commitment to domestic research and development and capital investments, including manufacturing, over the next decade.
The new facilities are described as state-of-the-art plants that will incorporate advanced manufacturing technologies to support AbbVie’s next generation of medicines. By concentrating additional production in the United States, the company aims to reinforce the resilience of its supply chain for complex therapeutics while aligning capital investment with its long-term R&D pipeline.
Construction of the two buildings is scheduled to begin in spring 2026 on AbbVie’s Illinois campus. The company expects both facilities to reach full operational status in 2029, marking a multiyear development and commissioning timetable. The expansion is focused on domestic production capacity for neuroscience and obesity medicines, reflecting strategic therapeutic areas where AbbVie is deploying both R&D and manufacturing resources.
To support the new facilities, AbbVie plans to add 300 positions in North Chicago. The hiring plan spans engineering, scientific, manufacturing and laboratory roles, including engineers, scientists, manufacturing operators and lab technicians. These roles are intended to staff the new operations once they are built out and brought online, complementing the company’s existing workforce at the Illinois campus.
AbbVie chairman and chief executive officer Robert A. Michael said the added U.S. manufacturing capacity is intended to underpin the company’s investment in innovation and strengthen its ability to deliver new medicines to patients. He framed the projects as part of a coordinated strategy to link R&D investment with domestic production capabilities that can support commercial-scale supply for complex therapies.
The announcement comes as broader industrial and life sciences users continue to deploy capital into specialized manufacturing facilities, including campuses tied to major corporate headquarters or R&D hubs. AbbVie’s latest investment underscores ongoing demand for highly technical industrial space that can accommodate advanced production processes and stringent regulatory requirements.
Separately, Connect Industrial Midwest is scheduled to feature Carter Andrus, chief operating officer of Prologis, as the keynote interview. The event is set for Tuesday afternoon, March 10, 2026, at Joe’s Live in Rosemont, Illinois, and is positioned as a forum for discussing trends across the industrial property sector.
“}]]
